

Mitra Biotech announces CAP accreditation

05 March 2018 | News

Founded in 2010, Mitra is headquartered in Greater Boston and maintains a significant research and laboratory presence in Bengaluru, India. An accomplished leadership team of industry professionals heads the company, with a dedicated focus on enhancing the personalization of cancer treatment and care worldwide.



Mitra Biotech, a global leader in advancing the personalization of cancer treatment, has announced that its Woburn, MA laboratory facility is now accredited by the College of American Pathologists (CAP) Laboratory Accreditation Program.

Mitra's CANscript platform recreates a patient's own tumor microenvironment in vitro, measures multiple parameters to determine whether a tumor is responding to physician-selected treatments, and then converts these parameters into a single score that predicts clinical response to each of the physician-selected therapies.

According to CAP's website, the Laboratory Accreditation Program inspects a variety of laboratory settings from complex university medical centers to physician office laboratories, and covers a complete array of disciplines and testing procedures. This peer-based inspection model helps laboratories:

- Meet Clinical Laboratory Improvement Amendments (CLIA) Regulatory Requirements,
- Ensure compliance through the guidance of the most comprehensive scientifically endorsed laboratory standards,
- Maintain accuracy of test results and ensure accurate patient diagnosis, and
- Increase the value they bring to organizations, customers, and patients.

"We're dedicated to being a leader in advancing patient care," said Mallik Sundaram, Mitra CEO and Co-Founder. "The CAP accreditation reflects the high standards to which we hold ourselves accountable, and we are honored to receive this prestigious recognition."

CANscript delivers powerful, individualized treatment response predictions — with exceptionally high correlation to clinical outcomes — to inform patient-specific cancer treatment selection and support more effective and efficient cancer drug development. CANscript has been validated using thousands of cancer cases, with a published 90% overall correlation between the platform's treatment predictions and actual clinical outcomes.

Founded in 2010, Mitra is headquartered in Greater Boston and maintains a significant research and laboratory presence in Bengaluru, India. An accomplished leadership team of industry professionals heads the company, with a dedicated focus on enhancing the personalization of cancer treatment and care worldwide.